Navigation Links
Canopus BioPharma Strengthens its CB1400 Platform Technology for Mucositis and Oncology Treatments Through License Agreement With Wisconsin Alumni Research Foundation
Date:6/18/2008

LOS ANGELES, California, June 18 /PRNewswire-FirstCall/ -- Canopus BioPharma, Inc. (OTC: CBIA), a biotechnology company developing pharmaceutical products and assay methods for patients suffering from infectious disease, radiation sickness, cancer and addiction, today announced the signing of a licensing agreement with the Wisconsin Alumni Research Foundation (WARF), an organization serving the University of Wisconsin-Madison scientific community by patenting the discoveries of UW-Madison researchers and licensing these technologies to leading companies in Wisconsin, the United States and worldwide. The agreement provides comprehensive licensing rights and patent protection relating to Canopus' Phase II oncology drug candidate, CB1400.

"Securing the rights to the WARF patents strengthens Canopus BioPharma's intellectual property position for future licensing opportunities of CB1400, one of our most exciting products," said Patrick Prendergast, Chairman and Chief Executive Officer of Canopus BioPharma. "In the near future, we expect to announce important results from our studies using CB1400, which will further validate the potential significance of our drug for oncology and related indications."

Canopus BioPharma expects to develop CB1400 as a method for preventing and reducing mucositis (lesions in the gastrointestinal and oral mucosa caused by chemo- and/or radiotherapy). The domestic market alone for a preventative anti-mucositis agent is estimated to be over $1 billion per annum. The compound underlying CB1400 had been previously developed and patented by a major pharmaceutical company as an anti-parasitic agent. Canopus discovered that this approved drug was highly effective for an alternative indication, specifically for use in preventing mucositis. Canopus BioPharma's market opportunity with CB1400 includes various applications associated with cancer therapy and cancer treatment side effects.

CB1400, a former anti-schistosomal drug
'/>"/>

SOURCE Canopus BioPharma, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
2. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
3. Nabi Biopharmaceuticals Announces Continued Positive NicVAX Phase 2b Data at Nine Months
4. Keryx Biopharmaceuticals to Present at William Blair & Company Small-Cap Growth Stock Conference
5. Morria Biopharmaceuticals Plc Initiates Phase I Clinical Study of MRX-4 in Allergic Rhinitis
6. Keryx Biopharmaceuticals, Inc. Announces Positive Preliminary Phase 2 Data on KRX-0401 in Patients with Chemo-Insensitive Rare Sarcoma
7. Nabi Biopharmaceuticals Announces Successful Completion of NicVAX(R) Phase 2b Trial; Drug Shows Statistically Significant Rates of Smoking Cessation and Continuous Long-Term Smoking Abstinence at 12 Months
8. Inspiration Biopharmaceuticals Announces Filing of IND for Novel Recombinant Factor IX Product, IB1001, for the Treatment of Hemophilia B
9. Immunosyn Announces Biozyme Labs Receipt of MHRA Manufacturing License Approval in Europe for the Biopharmaceutical SF-1019
10. Keryx Biopharmaceuticals, Inc. Announces Phase 1 and Phase 2 Data on KRX-0401 (Perifosine) in Patients with Relapsed/Refractory Multiple Myeloma at 49th Annual Meeting of American Society of Hematology
11. XTL Biopharmaceuticals Presents Data Regarding its Hepatitis C Virus Small Molecule Program at Hep Dart 2007 - an International Scientific Conference on Viral Hepatitis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/19/2014)... , Dec. 18, 2014  RESMED INC. (NYSE: ... second quarter of fiscal year 2015 results on Thursday, January ... A press release with ResMed,s results will be issued after ... a webcast to discuss operating results and future outlook. ... p.m. US Pacific Time and the live webcast of the ...
(Date:12/19/2014)... separating membrane market has witnessed robust development with the ... as a later starter. In 2012, the size of ... billion, with the proportion worldwide soaring to 16.3%. It is ... will continue its growth rate by around 20% in the ... to roughly RMB25 billion. An integrated membrane industrial ...
(Date:12/17/2014)... N.Y. , Dec. 17, 2014  Northstar ... The Depository Trust Company (DTC) has made their ... Deposit Chill on the Company,s stock effective December ... Northstar,s common stock for depository and book entry ... the Company is now once again fully "DTC ...
Breaking Medicine Technology:ResMed To Announce Second Quarter 2015 Results 2Separation Membranes Market (Company, Country & Application) Research Reports for Global and Chinese Regions 2Separation Membranes Market (Company, Country & Application) Research Reports for Global and Chinese Regions 3Northstar announces that the DTC chill on MDIN has been officially lifted 2Northstar announces that the DTC chill on MDIN has been officially lifted 3
(Date:12/19/2014)... TX (PRWEB) December 19, 2014 ... a shifting, capital equipment market that is saturated ... impressive safety and efficacy as well as non-invasive ... they were first introduced to the healthcare market. ... the development of MRI safe technologies have greatly ...
(Date:12/19/2014)... From November 24, 2014, Siddhi Yoga ... 2014 in its Goa retreat . This is the ... winters, from November to March, Siddhi Yoga will organize four ... Goa. The Goa training sessions will conclude in March 2015. ... training, the 10th intake is also a 200 YTT ...
(Date:12/19/2014)... Wilmington, VT (PRWEB) December 19, 2014 ... full-service private ski club in Southern Vermont’s Deerfield Valley, ... trail names inspired by classic rock songs. , ... the weekend with a private concert followed by a ... said, “The new trail names include: “I’m Alright” the ...
(Date:12/19/2014)... HealthDay Reporter THURSDAY, ... ibuprofen, might slightly reduce your risk of developing a ... ibuprofen (Advil, Motrin) and naproxen (Aleve) appear to reduce ... percent, the researchers concluded after reviewing nine prior studies. ... exposure. These painkillers "have potential as ...
(Date:12/17/2014)... 17, 2014 Dr. Myo Nwe is the ... Diet of the Future” and co-founder of the Ace Medical ... Dr. Nwe takes a broad look at the industry of ... under scientific scrutiny. On film and in television shows, however, ... toward the social aspects and played for basic laughs, which ...
Breaking Medicine News(10 mins):Health News:Magnetic Resonance Imaging Systems Market Analysis and Forecast to 2020 Report at RnRMarketReserach.com 2Health News:Magnetic Resonance Imaging Systems Market Analysis and Forecast to 2020 Report at RnRMarketReserach.com 3Health News:Magnetic Resonance Imaging Systems Market Analysis and Forecast to 2020 Report at RnRMarketReserach.com 4Health News:Siddhi Yoga’s 10th intake of YTT started in Goa on November 24, 2014 2Health News:Siddhi Yoga’s 10th intake of YTT started in Goa on November 24, 2014 3Health News:The Hermitage Club Officially Names Four Ski Trails after Iconic Rock Songs by Grammy Award Winner Kenny Loggins 2Health News:Common Painkillers May Help Prevent Certain Skin Cancers, Study Finds 2Health News:Common Painkillers May Help Prevent Certain Skin Cancers, Study Finds 3Health News:Obesity Should Not Be a Hollywood Punchline, Weight Loss Doc Says 2
... ... heart function without need for cardiac stem cells , ... (Vocus) July 16, 2009 -- Injured heart tissue normally can,t regrow, ... heart tissue after a heart attack, in patients with heart failure, or in children with ...
... coronary function are restored , THURSDAY, JULY 23 (HealthDay ... tissue renew itself after a heart attack -- until now. ... to the heart become blocked, preventing enough oxygen from getting ... But researchers at Children,s Hospital Boston report progress toward someday ...
... , , PIPERSVILLE, Pa., July 23 ... the body,s mechanism for cooling itself is overactive and can cause ... than normal. While some people may only think about sweating during ... can disrupt their daily and recreational activities, regardless of the season. ...
... , ROANOKE, Va., July 23 Job ... The Virginia Psychological Association (VPA) and Virginia Academy of Clinical ... this cost by awarding the 2009 VPA/VACP Psychologically Healthy Workplace ... submit nominations. , , ...
... , , LOS ANGELES, July 23 ... AIDS Programs and Policy is launching its most comprehensive community outreach campaign ... of those who have HIV does not know it. , ... Titled "Virus," the multi-faceted campaign is designed to raise doubt ...
... , INDIANAPOLIS, July 23 Today, Eli ... the U.S. Food and Drug Administration (FDA) has approved a ... injection] to treat osteoporosis associated with sustained, systemic glucocorticoid therapy ... therapy is the most common cause of secondary osteoporosis, leading ...
Cached Medicine News:Health News:Study in this Week's Issue of Cell Finds Injected Growth Factor Spurs Heart Regeneration 2Health News:Study in this Week's Issue of Cell Finds Injected Growth Factor Spurs Heart Regeneration 3Health News:Injection May Heal Damaged Heart 2Health News:Photos: Don't Let Them See You Sweat This Summer 2Health News:Photos: Don't Let Them See You Sweat This Summer 3Health News:Photos: Don't Let Them See You Sweat This Summer 4Health News:Photos: Don't Let Them See You Sweat This Summer 5Health News:Los Angeles County Launches Its Most Comprehensive Campaign Ever to Encourage HIV Testing 2Health News:Los Angeles County Launches Its Most Comprehensive Campaign Ever to Encourage HIV Testing 3Health News:FDA Approves Expanded Use of Lilly's FORTEO(R) [teriparatide (rDNA origin) injection] to Treat Glucocorticoid-Induced Osteoporosis 2Health News:FDA Approves Expanded Use of Lilly's FORTEO(R) [teriparatide (rDNA origin) injection] to Treat Glucocorticoid-Induced Osteoporosis 3Health News:FDA Approves Expanded Use of Lilly's FORTEO(R) [teriparatide (rDNA origin) injection] to Treat Glucocorticoid-Induced Osteoporosis 4Health News:FDA Approves Expanded Use of Lilly's FORTEO(R) [teriparatide (rDNA origin) injection] to Treat Glucocorticoid-Induced Osteoporosis 5Health News:FDA Approves Expanded Use of Lilly's FORTEO(R) [teriparatide (rDNA origin) injection] to Treat Glucocorticoid-Induced Osteoporosis 6
Anterior Chamber Needle, 21 g., 8 mm from bend to tip. Overall length 25 mm. 5/box....
Anterior Chamber Needle, 30 g. Angled. 5 mm angled tip. Overall length 20 mm. 5/box....
Anterior Chamber Needle, 23 g. Angled. 7 mm angled tip. Overall length 23 mm. 5/box....
Anterior Chamber Needle, 20 g. Angled. 7 mm angled tip. Overall length 23 mm. 5/box....
Medicine Products: